In late October 2018, Collplant Holdings Ltd ADR (NASDAQ:CLGN) announced a licensing, development and commercialisation agreement for 3D bioprinted lung transplants using rhCollagen-based BioInk. This news follows the United Therapeutics’ Science Day in September, where its founder and CEO presented the company’s R&D using CollPlant’s rhCollagen to 3D bioprint lung scaffolds. This co-development agreement further validates CollPlant’s technology.
rhCollagen-based BioInk co-development agreement
On 22 October 2018, CollPlant announced a licensing, development and commercialisation agreement with United Therapeutics for 3D bioprinted lung transplants using CollPlant’s proprietary rhCollagen-based BioInk. The agreement entitles CollPlant to a $5m upfront payment and up to $15m in additional milestone payments for the development of 3D bioprinting lung scaffolds for human transplants. The agreement also enables United Therapeutics to expand its licence to utilise BioInk for the development of three additional organs, which in turn may generate more financial upside for CollPlant, with an additional $9m upfront payment and up to another $15m in milestones. Furthermore, CollPlant is entitled to royalties on sales.
To read the entire report Please click on the pdf File Below..